<DOC>
	<DOCNO>NCT03029442</DOCNO>
	<brief_summary>The purpose study determine usefulness drug , denosumab , prevent loss bone participant legs due SCI . This drug FDA approve treat osteoporosis woman menopause increase risk fracture , treat woman receive certain treatment breast cancer increase risk fracture , treat bone loss men receive certain treatment prostate cancer increase risk fracture . This drug consider experimental purpose study . Study participation last approximately 12 month ( 6 study visit total ) , visit range from1-4.5 hour depend number test need complete . The study double-blinded placebo trail participant randomly assign two group , Denosumab injection placebo - inactive salt solution injection .</brief_summary>
	<brief_title>The Efficacy Denosumab Incomplete Patients Spinal Cord Injury</brief_title>
	<detailed_description>The primary objective study test efficacy potent anti-resorptive agent , denosumab [ receptor activator nuclear factor-κB ligand ( RANKL ) antibody ; Amgen Inc. ] preserve bone mass hip knee trabecular connectivity knee subacute motor-incomplete SCI [ American Spinal Injury Association ( AIS ) neurological classification scale C D ] James J. Peters VA Medical Center ( JJPVAMC ) Kessler Institute Rehabilitation ( KIR ) . A randomized , double-blind , placebo-controlled , parallel group trial perform thirty-two subject acute , motor-incomplete SCI ( ≤6 month ) admit JJPVAMC KIR . Denosumab ( 60 mg SC ) administer baseline , 6 , 12 month ; placebo group receive normal saline subcutaneously . Denosumab administer soon possible , 24 week , SCI . The last dose denosumab placebo administer 6 month , anticipated effect drug persist inhibit bone resorption least 12 month time point .</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>1 . Motor incomplete SCI [ American Spinal Injury Association Impairment Scale ( AIS ) grade C D ] ; 2 . Duration injury &lt; 6months ; 3 . Males age 18 65 year old female age 18 50 year old . 1 . Extensive lifethreatening injury addition SCI ; 2 . Acute fracture extensive bone trauma ; 3 . History prior bone disease ( Paget 's hyperparathyroidism , osteoporosis , etc . ) 4 . Postmenopausal woman ; 5 . Men know hypogonadism prior SCI ; 6 . Anabolic Steroid hormonal therapy ; within past year longer six month ; 7 . Hyperthyroidism ; 8 . Cushing 's disease syndrome ; 9 . Severe underlie chronic disease ; 10 . History chronic alcohol abuse ; 11 . Diagnosis Hypocalcemia ; 12 . Pregnancy ; 13 . Existing dental condition/dental infection ; 14 . Diagnosis heterotopic ossification hip and/or knee region receive bisphosphonates [ e.g . alendronate sodium ( Fosamax ) etidronate disodium ( Didronel ) ] longer make participant eligible receive study medication/placebo still eligible complete followup outcome measure describe work schedule ; 15 . Current diagnosis cancer history cancer ; 16 . Any patient receiving moderate high dose corticosteroid ( &gt; 40 mg/d prednisone equivalent dose corticosteroid ) long one week , include drug administer attempt preserve neurological function time acute SCI .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Spinal Cord Injury</keyword>
	<keyword>Denosumab</keyword>
	<keyword>Osteoporosis</keyword>
	<keyword>Dual Energy X-ray Absorptiometry</keyword>
</DOC>